ArticleFrontiers in pharmacology2022

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma

Zhi-Yong Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.